$945 Million is the total value of Aquilo Capital Management, LLC's 17 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 35.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Buy | SPDR SER TR S&P BIOTECHput | $445,720,000 | +99.1% | 4,000,000 | +100.0% | 47.19% | +4.5% |
| IWM | New | ISHARES TR RUSSELL 2000put | $254,643,000 | – | 1,700,000 | +100.0% | 26.96% | – |
| SPRO | Buy | SPERO THERAPEUTICS INC | $50,188,000 | +90.9% | 4,497,142 | +131.4% | 5.31% | +0.2% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $35,757,000 | +45.5% | 385,727 | +22.4% | 3.78% | -23.6% |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $24,732,000 | -33.1% | 1,374,776 | -5.5% | 2.62% | -64.9% |
| QURE | Sell | UNIQURE NV | $23,242,000 | -24.1% | 631,060 | -7.1% | 2.46% | -60.2% |
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $22,538,000 | -7.4% | 523,415 | -7.1% | 2.39% | -51.4% |
| ANAB | Sell | ANAPTYSBIO INC | $21,795,000 | -38.7% | 1,477,652 | -7.1% | 2.31% | -67.8% |
| NGM | Sell | NGM BIOPHARMACEUTICALS INC | $16,202,000 | -25.1% | 1,018,334 | -7.0% | 1.72% | -60.7% |
| RGNX | Sell | REGENXBIO INC | $14,056,000 | -31.0% | 510,760 | -7.7% | 1.49% | -63.8% |
| PRQR | Sell | PROQR THRAPEUTICS N V | $10,931,000 | -25.1% | 2,281,966 | -5.0% | 1.16% | -60.7% |
| PIRS | Sell | PIERIS PHARMACEUTICALS INC | $7,608,000 | -56.0% | 3,675,530 | -34.1% | 0.80% | -76.9% |
| MGTA | New | MAGENTA THERAPEUTICS INC | $6,519,000 | – | 958,618 | +100.0% | 0.69% | – |
| GLPG | Sell | GALAPAGOS NVspon adr | $4,617,000 | -47.1% | 32,534 | -26.5% | 0.49% | -72.2% |
| ACIU | New | AC IMMUNE SA | $2,262,000 | – | 463,575 | +100.0% | 0.24% | – |
| ARGX | Sell | ARGENX SEsponsored adr | $1,969,000 | -75.6% | 7,500 | -79.1% | 0.21% | -87.2% |
| GMAB | New | GENMAB A/Ssponsored ads | $1,831,000 | – | 50,000 | +100.0% | 0.19% | – |
| MOR | Exit | MORPHOSYS AGsponsored ads | $0 | – | -95,898 | -100.0% | -0.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.